X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (2780) 2780
Book Review (350) 350
Publication (270) 270
Book Chapter (10) 10
Conference Proceeding (6) 6
Book / eBook (3) 3
Dissertation (2) 2
Magazine Article (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
index medicus (2698) 2698
humans (1927) 1927
animals (1205) 1205
pharmacology & pharmacy (1189) 1189
male (1136) 1136
aryl hydrocarbon hydroxylases - metabolism (873) 873
aryl hydrocarbon hydroxylases - antagonists & inhibitors (864) 864
female (774) 774
aryl hydrocarbon hydroxylases - genetics (772) 772
aryl hydrocarbon hydroxylases (654) 654
cytochrome p-450 enzyme inhibitors (639) 639
cytochrome p-450 enzyme system - metabolism (614) 614
rats (602) 602
enzyme inhibitors - pharmacology (546) 546
cytochrome p-450 cyp3a (540) 540
cytochrome p-450 cyp2c9 (524) 524
microsomes, liver - enzymology (522) 522
metabolism (507) 507
cytochrome p-450 cyp2c19 (472) 472
drug interactions (410) 410
cytochrome p-450 (395) 395
adult (378) 378
toxicology (373) 373
microsomes, liver - drug effects (353) 353
mice (351) 351
kinetics (343) 343
middle aged (331) 331
genotype (326) 326
biochemistry & molecular biology (320) 320
pharmacokinetics (317) 317
dose-response relationship, drug (310) 310
cytochrome p-450 enzyme system - genetics (304) 304
in-vitro (304) 304
oxidoreductases, n-demethylating - antagonists & inhibitors (293) 293
mixed function oxygenases - antagonists & inhibitors (274) 274
cytochrome p450 (271) 271
mixed function oxygenases - metabolism (266) 266
mixed function oxygenases - genetics (263) 263
microsomes, liver - metabolism (257) 257
in vitro techniques (253) 253
enzymes (252) 252
oxidoreductases, n-demethylating - metabolism (252) 252
human liver-microsomes (250) 250
hydroxylation (238) 238
liver - enzymology (236) 236
inhibition (234) 234
aged (229) 229
expression (228) 228
pharmacogenetics (214) 214
cytochrome p-450 cyp1b1 (205) 205
polymorphism, genetic (205) 205
abridged index medicus (198) 198
cells, cultured (197) 197
aryl-hydrocarbon receptor (196) 196
induction (193) 193
steroid hydroxylases - antagonists & inhibitors (190) 190
physiological aspects (177) 177
cyp2c9 (176) 176
liver - drug effects (175) 175
steroid hydroxylases - metabolism (175) 175
rats, sprague-dawley (174) 174
warfarin (170) 170
biotransformation (168) 168
steroid 16-alpha-hydroxylase (165) 165
enzyme induction - drug effects (164) 164
liver (160) 160
cytochrome p450 family 2 (159) 159
identification (153) 153
cytochrome p-450 cyp2a6 (150) 150
analysis (149) 149
research (149) 149
chromatography, high pressure liquid (148) 148
area under curve (147) 147
gene-expression (145) 145
ticlopidine - analogs & derivatives (145) 145
cytochrome p-450 cyp2b6 (144) 144
cytochrome p-450 enzyme system - biosynthesis (144) 144
receptors, aryl hydrocarbon - metabolism (144) 144
time factors (140) 140
liver - metabolism (138) 138
aryl hydrocarbon hydroxylases - biosynthesis (137) 137
cytochrome p-450 cyp1a1 - metabolism (134) 134
recombinant proteins - metabolism (134) 134
enzyme induction (128) 128
cytochrome p-450 cyp1a1 - genetics (127) 127
oncology (126) 126
rna, messenger - metabolism (126) 126
article (125) 125
substrate specificity (125) 125
pharmacology/toxicology (123) 123
cytochrome p-450 cyp2c8 (122) 122
cancer (119) 119
cross-over studies (118) 118
isoenzymes - metabolism (118) 118
structure-activity relationship (118) 118
genetic aspects (116) 116
anticoagulants - administration & dosage (114) 114
polymorphism (113) 113
rats, wistar (113) 113
vitamin k epoxide reductases (113) 113
more...
Library Location Library Location
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (2727) 2727
Russian (17) 17
Japanese (14) 14
Chinese (8) 8
Spanish (7) 7
German (5) 5
French (4) 4
Polish (3) 3
Danish (1) 1
Norwegian (1) 1
Romanian (1) 1
Swedish (1) 1
Ukrainian (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Drug Metabolism and Disposition, ISSN 0090-9556, 01/2010, Volume 38, Issue 1, pp. 92 - 99
The aim of the current study is to identify the human cytochrome P450 (P450) isoforms involved in the two oxidative steps in the bioactivation of clopidogrel... 
MECHANISM-BASED INHIBITION | ANTIAGGREGATING ACTIVITY | POLYMORPHISMS | TICLOPIDINE | PHARMACOKINETICS | HEALTHY-SUBJECTS | PHARMACOLOGY & PHARMACY | PRASUGREL | PHARMACODYNAMICS | MONOCLONAL-ANTIBODIES | ATORVASTATIN | Microsomes - metabolism | Humans | Aryl Hydrocarbon Hydroxylases - genetics | Cytochrome P-450 Enzyme System - metabolism | Sulfaphenazole - pharmacology | Microsomes - drug effects | Cytochrome P-450 CYP3A - genetics | Cytochrome P-450 CYP1A2 - genetics | Antibodies - immunology | Omeprazole - pharmacology | Microsomes, Liver - enzymology | Platelet Aggregation Inhibitors - pharmacokinetics | Ticlopidine - pharmacokinetics | Oxidoreductases, N-Demethylating - metabolism | Aryl Hydrocarbon Hydroxylases - immunology | Oxidation-Reduction | Enzyme Inhibitors - pharmacology | Ticlopidine - analogs & derivatives | Oxidoreductases, N-Demethylating - immunology | Cytochrome P-450 CYP3A - metabolism | Cell Line, Tumor | Cytochrome P-450 Enzyme System - genetics | Theophylline - pharmacology | Kinetics | Cytochrome P-450 CYP2C9 | Theophylline - analogs & derivatives | Oxidoreductases, N-Demethylating - genetics | Glutathione - metabolism | Ketoconazole - pharmacology | Biotransformation - physiology | Cytochrome P-450 CYP1A2 Inhibitors | Microsomes, Liver - drug effects | Ticlopidine - metabolism | NADP - metabolism | Platelet Aggregation Inhibitors - metabolism | Cytochrome P-450 CYP3A - immunology | Cell Line | Aryl Hydrocarbon Hydroxylases - antagonists & inhibitors | Cytochrome P-450 CYP1A2 - immunology | Biocatalysis | Mephenytoin - analogs & derivatives | Cytochrome P-450 CYP1A2 - metabolism | Aryl Hydrocarbon Hydroxylases - metabolism | Mephenytoin - pharmacology | Antibodies - pharmacology | Cytochrome P-450 CYP3A Inhibitors | Cytochrome P-450 CYP2C19 | Clopidogrel | Cytochrome P-450 CYP2B6 | Index Medicus
Journal Article
Circulation, ISSN 0009-7322, 08/2012, Volume 126, Issue 9, pp. 1087 - 1098
Background-Pulmonary arterial hypertension (PAH) is a hyperproliferative vascular disorder observed predominantly in women. Estrogen is a potent mitogen in... 
Hypertension | Animal | Estrogens | Models | Cardiovascular diseases | Metabolism | Pulmonary | models animal | SEROTONIN TRANSPORTER | CARDIAC & CARDIOVASCULAR SYSTEMS | hypertension pulmonary | P450CYP1B1 | estrogens | cardiovascular diseases | P4501B1 CYP1B1 | HYPOXIA | BREAST-CANCER | IN-VIVO | ESTRADIOL | GENE-EXPRESSION | PERIPHERAL VASCULAR DISEASE | metabolism | MICE | 2-METHOXYESTRADIOL | Up-Regulation | Aryl Hydrocarbon Hydroxylases - biosynthesis | Humans | Aryl Hydrocarbon Hydroxylases - genetics | Myocytes, Smooth Muscle - pathology | Male | Stilbenes - pharmacology | Hypertension, Pulmonary - chemically induced | Lung - enzymology | Cell Hypoxia | Hydroxyestrones - toxicity | Aryl Hydrocarbon Hydroxylases - physiology | Female | Estrogens - metabolism | Myocytes, Smooth Muscle - metabolism | Estradiol - pharmacology | Hypertension, Pulmonary - enzymology | Aryl Hydrocarbon Hydroxylases - antagonists & inhibitors | Cells, Cultured - drug effects | Lung - pathology | Hydroxyestrones - pharmacology | Enzyme Induction | Hypoxia - complications | Hypertrophy, Right Ventricular - enzymology | Reverse Transcriptase Polymerase Chain Reaction | Pulmonary Artery - enzymology | Mice, Knockout | Animals | Aryl Hydrocarbon Hydroxylases - deficiency | Hydroxyestrones - metabolism | Cytochrome P-450 CYP1B1 | Cells, Cultured - metabolism | Mice | Chronic Disease | Hypertension, Pulmonary - etiology | Hypertension, Pulmonary - pathology | Pulmonary Artery - pathology | Physiological aspects | Development and progression | Research | Pulmonary hypertension | Cytochrome P-450 | Estrogen | Index Medicus | Abridged Index Medicus
Journal Article
Journal of Thrombosis and Haemostasis, ISSN 1538-7933, 11/2006, Volume 4, Issue 11, pp. 2508 - 2509
HEMATOLOGY | PERIPHERAL VASCULAR DISEASE | Ticlopidine - pharmacology | Humans | Aryl Hydrocarbon Hydroxylases - genetics | Ticlopidine - antagonists & inhibitors | Male | Mixed Function Oxygenases - metabolism | Omeprazole - antagonists & inhibitors | Phosphoproteins - metabolism | Coronary Disease - metabolism | Protein Processing, Post-Translational - drug effects | Coronary Disease - complications | Platelet Aggregation Inhibitors - pharmacology | Female | Omeprazole - pharmacology | Microfilament Proteins - metabolism | Aspirin - pharmacology | Phosphorylation - drug effects | Aspirin - antagonists & inhibitors | Aryl Hydrocarbon Hydroxylases - antagonists & inhibitors | Platelet Function Tests - methods | Enzyme Inhibitors - pharmacology | Angioplasty - methods | Mixed Function Oxygenases - antagonists & inhibitors | Cell Adhesion Molecules - metabolism | Ticlopidine - analogs & derivatives | Aryl Hydrocarbon Hydroxylases - metabolism | Platelet Activation - genetics | Thrombosis - metabolism | Angioplasty - adverse effects | Coronary Disease - genetics | Drug Antagonism | Cytochrome P-450 CYP2C19 | Thrombosis - etiology | Thrombosis - genetics | Aged | Platelet Activation - drug effects | Polymorphism, Single Nucleotide | Coronary Disease - surgery | Mixed Function Oxygenases - genetics | Index Medicus | Phosphorylation | Enzyme Inhibitors | Angioplasty | Cell Adhesion Molecules | Mixed Function Oxygenases | Life Sciences | Coronary Disease | Phosphoproteins | Platelet Function Tests | Aspirin | Thrombosis | Ticlopidine | Omeprazole | Human health and pathology | Microfilament Proteins | Platelet Activation | Platelet Aggregation Inhibitors | Protein Processing, Post-Translational | Aryl Hydrocarbon Hydroxylases
Journal Article
PLoS ONE, ISSN 1932-6203, 2011, Volume 6, Issue 3, pp. e17979 - e17979
EGFR-MEK-ERK signaling pathway has an established role in promoting malignant growth and disease progression in human cancers. Therefore identification of... 
TRANSCRIPTION FACTORS | HUMAN MALIGNANCIES | GASTRIC-CANCER | PATHWAY | GROWTH | BIOLOGY | GENE-EXPRESSION | ACUTE MYELOID-LEUKEMIA | ONCOGENIC ACTIVITY | EGFR | FAMILY | Promoter Regions, Genetic | Aryl Hydrocarbon Hydroxylases - antagonists & inhibitors | Humans | Aryl Hydrocarbon Hydroxylases - genetics | Molecular Sequence Data | MAP Kinase Kinase 1 - metabolism | MAP Kinase Kinase 2 - metabolism | DNA Methylation | Base Sequence | DNA | Steroid Hydroxylases - antagonists & inhibitors | Cell Line, Tumor | Proto-Oncogene Protein c-ets-1 - physiology | Polymorphism, Single Nucleotide | Steroid Hydroxylases - genetics | Chromatin | Phosphatases | RNA | Luciferase | Cancer cells | Development and progression | Cancer | Biotechnology | Transcription factors | Ets-1 protein | Immunoprecipitation | Target recognition | Phosphoprotein phosphatase | Leukemia | Stimulation | Biology | Kinases | Phosphatase | Proteins | Angiogenesis | Signal transduction | Evolutionary conservation | Rodents | DNA methylation | Inhibition | Deoxyribonucleic acid--DNA | CpG islands | Antigens | Sequences | Medical technology | Epidermal growth factor receptors | Cloning | Extracellular signal-regulated kinase | Gene expression | Signaling | Hospitals | Inhibitors | Mutagenesis | Adenoviruses | Regulatory mechanisms (biology) | Protein phosphatase | Mutation | Binding sites | Data processing | siRNA | Promoters | Index Medicus | Basic Medicine | Steroid Hydroxylases: antagonists & inhibitors | MAP Kinase Kinase 1: metabolism | Medical and Health Sciences | Medicin och hälsovetenskap | Aryl Hydrocarbon Hydroxylases: antagonists & inhibitors | Aryl Hydrocarbon Hydroxylases: genetics | Steroid Hydroxylases: genetics | Medicinsk genetik | Medical Genetics | Medicinska och farmaceutiska grundvetenskaper | Proto-Oncogene Protein c-ets-1: physiology | MAP Kinase Kinase 2: metabolism | Deoxyribonucleic acid
Journal Article
Drug Metabolism and Disposition, ISSN 0090-9556, 08/2007, Volume 35, Issue 8, pp. 1400 - 1407
The elimination process of the endothelin receptor antagonist bosentan (Tracleer) in humans is entirely dependent on metabolism mediated by two cytochrome P450... 
PHARMACOKINETICS | METABOLISM | HEALTHY MALE-SUBJECTS | PHARMACOLOGY & PHARMACY | ANION TRANSPORTING POLYPEPTIDES | HUMAN LIVER | RIFAMYCIN SV | EXPRESSION | DISPOSITION | ENDOTHELIN RECEPTOR ANTAGONIST | DRUG-DRUG INTERACTION | Cytochrome P-450 CYP2C9 | Organic Anion Transporters, Sodium-Independent - genetics | Estradiol - analogs & derivatives | Organic Anion Transporters, Sodium-Independent - antagonists & inhibitors | Cricetulus | Cytochrome P-450 Enzyme Inhibitors | Cyclosporine - pharmacology | Cytochrome P-450 CYP3A | Humans | Warfarin - metabolism | Cytochrome P-450 Enzyme System - metabolism | Dehydroepiandrosterone Sulfate - metabolism | Sulfones - pharmacology | Organic Anion Transporters - metabolism | Pyrimidines - chemistry | Pyrimidines - metabolism | Sildenafil Citrate | Organic Anion Transporters - genetics | Bosentan | Drug Interactions | Organic Anion Transporters, Sodium-Independent - metabolism | Biological Transport - drug effects | Molecular Structure | Solute Carrier Organic Anion Transporter Family Member 1B3 | CHO Cells | Estradiol - metabolism | Aryl Hydrocarbon Hydroxylases - antagonists & inhibitors | Cricetinae | Organic Anion Transporters - antagonists & inhibitors | Sulfonamides - chemistry | Purines - pharmacology | Enzyme Inhibitors - pharmacology | Piperazines - pharmacology | Sulfonamides - pharmacokinetics | Aryl Hydrocarbon Hydroxylases - metabolism | Animals | Estrone - analogs & derivatives | Estrone - metabolism | Sulfonamides - metabolism | Liver-Specific Organic Anion Transporter 1 | Rifampin - pharmacology | Index Medicus
Journal Article
Journal Article
Journal Article
Journal Article
Clinical Pharmacology & Therapeutics, ISSN 0009-9236, 01/2011, Volume 89, Issue 1, pp. 65 - 74
Four randomized, placebo‐controlled, crossover studies were conducted among 282 healthy subjects to investigate whether an interaction exists between... 
VARIABILITY | LANSOPRAZOLE | RABEPRAZOLE | THERAPY | CARDIOVASCULAR EVENTS | STENT PLACEMENT | PHARMACOLOGY & PHARMACY | OUTCOMES | ANTIPLATELET ACTION | PROTON-PUMP INHIBITORS | DRUG-INTERACTION | Proton Pump Inhibitors - pharmacology | Ticlopidine - pharmacology | Humans | Middle Aged | Half-Life | Male | 2-Pyridinylmethylsulfinylbenzimidazoles - pharmacology | Enzyme Inhibitors - administration & dosage | Platelet Aggregation Inhibitors - blood | Young Adult | Drug Interactions | Proton Pump Inhibitors - administration & dosage | Platelet Aggregation Inhibitors - pharmacology | Adult | Female | Omeprazole - pharmacology | Platelet Aggregation - drug effects | Platelet Aggregation Inhibitors - pharmacokinetics | Ticlopidine - pharmacokinetics | Enzyme Inhibitors - adverse effects | Proton Pump Inhibitors - adverse effects | Aryl Hydrocarbon Hydroxylases - antagonists & inhibitors | Double-Blind Method | Drug Administration Schedule | 2-Pyridinylmethylsulfinylbenzimidazoles - adverse effects | Omeprazole - administration & dosage | Enzyme Inhibitors - pharmacology | Omeprazole - adverse effects | Ticlopidine - analogs & derivatives | Cross-Over Studies | Prodrugs - adverse effects | Prodrugs - pharmacokinetics | Cytochrome P-450 CYP2C19 | Platelet Activation - drug effects | 2-Pyridinylmethylsulfinylbenzimidazoles - administration & dosage | Prodrugs - pharmacology | Ticlopidine - blood | Omeprazole | Pantoprazole | Drug interactions | Analysis | Dosage and administration | Research | Patients | Health aspects | Index Medicus | Abridged Index Medicus
Journal Article
Pharmaceutical Research, ISSN 0724-8741, 4/2013, Volume 30, Issue 4, pp. 1188 - 1199
Quantitative prediction of complex drug-drug interactions (DDIs) is challenging. Repaglinide is mainly metabolized by cytochrome-P-450 (CYP)2C8 and CYP3A4, and... 
Biochemistry, general | Biomedical Engineering | repaglinide | CYP2C8 | Biomedicine | physiologically-based pharmacokinetic model | Pharmacy | Medical Law | Pharmacology/Toxicology | gemfibrozil | drug-drug interaction | OATP1B1 | GLUCURONIDE INHIBIT | IN-VITRO CLEARANCE | METABOLIC PATHWAYS | HUMAN LIVER-MICROSOMES | HEPATIC-UPTAKE | CHEMISTRY, MULTIDISCIPLINARY | INHIBITION MECHANISMS | SANDWICH CULTURE | PLASMA-CONCENTRATIONS | TISSUE DISTRIBUTION | PHARMACOLOGY & PHARMACY | Cytochrome P-450 CYP2C8 | Humans | Hepatocytes - metabolism | Carbamates - pharmacokinetics | Organic Anion Transporters - metabolism | Drug Interactions | Piperidines - pharmacology | Piperidines - pharmacokinetics | Hypolipidemic Agents - chemistry | Hepatocytes - drug effects | Carbamates - pharmacology | Cell Line | Aryl Hydrocarbon Hydroxylases - antagonists & inhibitors | Hypoglycemic Agents - pharmacokinetics | Organic Anion Transporters - antagonists & inhibitors | Biological Transport, Active - drug effects | Gemfibrozil - pharmacokinetics | Gemfibrozil - pharmacology | Hypolipidemic Agents - pharmacology | Aryl Hydrocarbon Hydroxylases - metabolism | Hypoglycemic Agents - pharmacology | Models, Biological | Gemfibrozil - analogs & derivatives | Hypolipidemic Agents - pharmacokinetics | Solute Carrier Organic Anion Transporter Family Member 1b1 | Side effects | Pharmacology | Liver | Pharmaceuticals | Index Medicus
Journal Article
Biochemistry, ISSN 0006-2960, 02/2018, Volume 57, Issue 5, pp. 817 - 826
Human hepatic cytochromes P450 (CYP)' are integral to xenobiotic metabolism. CYP2B6 is a major catalyst of biotransformation of environmental toxicants,... 
SIDE-CHAINS | ACTIVE-SITE | STRUCTURAL BASIS | BIOCHEMISTRY & MOLECULAR BIOLOGY | ESCHERICHIA-COLI | MAMMALIAN CYTOCHROME-P450 | LIVER-MICROSOMES | HUMAN CYTOCHROME-P450 2B6 | SITE-DIRECTED MUTAGENESIS | OXIDATIVE-METABOLISM | DRUG-METABOLISM | Cytochrome P-450 CYP2B1 - genetics | Aniline Compounds | Humans | Aryl Hydrocarbon Hydroxylases - genetics | NADPH Oxidases - metabolism | Substrate Specificity | Cytochrome P-450 Enzyme Inhibitors - metabolism | Structure-Activity Relationship | Environmental Pollutants - metabolism | Cytochromes b5 - metabolism | Cytochrome P-450 CYP2B6 - metabolism | Cytochrome P-450 CYP2B6 Inhibitors - metabolism | Cytochrome P-450 CYP2B6 - drug effects | Hydrocarbons, Halogenated - metabolism | Cytochrome P-450 CYP2B1 - chemistry | Cytochrome P450 Family 2 - genetics | Inhibitory Concentration 50 | Cytochrome P-450 CYP2B1 - metabolism | Molecular Structure | Aryl Hydrocarbon Hydroxylases - chemistry | Benzene Derivatives - pharmacology | Cytochrome P450 Family 2 - antagonists & inhibitors | Recombinant Proteins - metabolism | Rabbits | Aryl Hydrocarbon Hydroxylases - antagonists & inhibitors | Mutagenesis, Site-Directed | Oxidation-Reduction | Cytochrome P-450 CYP2B6 - genetics | Halogenated Diphenyl Ethers - pharmacology | Rats | Cytochrome P450 Family 2 - chemistry | Cytochrome P-450 CYP2B1 - antagonists & inhibitors | Aryl Hydrocarbon Hydroxylases - metabolism | Cytochrome P-450 CYP2B6 Inhibitors - pharmacology | Halogenated Diphenyl Ethers - metabolism | Cytochrome P-450 Enzyme Inhibitors - pharmacology | Animals | Cytochrome P450 Family 2 - metabolism | Alkylation - drug effects | Cytochrome P-450 CYP2B6 - chemistry | Amino Acid Substitution | Research | Chemical properties | Aniline | Cytochrome P-450 | Index Medicus
Journal Article